What Has Tanked Incyte and NewLink Genetics
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
The opioid epidemic in the U.S. cost employers $2.6 billion in 2016 to pay in treatment costs covered by insurance plans.
Conatus Pharmaceuticals shares took a big step back on Thursday after the firm announced that its midstage proof-of-concept clinical trial in liver transplant patients with fibrosis or cirrhosis failed to live up to expectations.
Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.
Celgene is shuffling the deck in terms of its executive leadership, and one of its top executives is stepping down.
Rigel Pharmaceuticals saw its shares pull back early on Tuesday after the firm announced topline data from a midstage study.
Pfizer shares took a small step back on Monday despite announcing positive results from a late-stage trial. The pullback seems to be the product of overall market sentiment as opposed to these results.
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
A California judge ruled that one ingredient in coffee was dangerous enough to be a potential cause of cancer. The judge made his decision on a limited amount of information.
Shares of Shire saw a solid gain on Wednesday after the firm announced that it received an offer to be acquired by Takeda Pharmaceutical.
Edge Therapeutics saw its shares plunge massively following the results from a late-stage trial.
Arrowhead Pharmaceuticals shares made a solid gain on Tuesday after the company gave an update on its midstage study of ARO-HBV in the treatment of patients with chronic hepatitis B virus infection.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.